Have gradual and progressive cognitive decline for greater than or equal to ( ≥) 6 months.
Have least 1 core clinical feature of dementia with Lewy bodies (DLB).
Have a score ≥20 on Montreal Cognitive Assessment (MoCA).
Meet plasma P-tau217 criteria.
Have a cerebrospinal fluid (CSF) result consistent with the presence of brain amyloid pathology.
Have a CSF result consistent with the presence of alpha-synuclein pathology.
Have at least 1 reliable study partner who will provide written informed consent to participate, is in frequent contact with the participant, and is familiar with overall function and behavior, such as day-to-day activities and cognitive abilities.
You may not be if
Have a disease or condition that could interfere with this study or is a current serious or unstable illness.
Have, or is suspected to have, a significant neurological disease (other than the studied condition) that affects the central nervous system and may affect the individual's cognition or ability to complete the study.
Have a history of cancer that, in the investigator's opinion, has a high risk of recurrence and preventing the completion of the study.
Have clinically significant multiple or severe drug allergies, significant atopy, or severe posttreatment hypersensitivity reactions.
Have previously received amyloid-targeting therapy.
Active immunization against amyloid-beta.
Have a centrally read MRI that does not meet study entry criteria.
Have contraindication to MRI or PET scans.
Have any contraindication to lumbar puncture.
Clareo Health | A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
